Drugs / Navax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07399717 | Jan → Dec 2026 expected | pneumonia | Anabio R&D | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Navax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07399717 ↗ |
| Known as | LiveSpo Navax | “In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device” NCT07399717 ↗ |
| Modality | Other / unclassified | “probiotic LiveSpo® Navax nasal-throat spray” NCT07399717 ↗ |
| Route | Other | “The nasal-oropharyngeal spray is administered as three sprays per nostril and throat per dose, three times daily” NCT07399717 ↗ |